Published in AIDS Res Treat on December 31, 2009
Factors associated with suboptimal adherence to antiretroviral therapy in Asia. J Int AIDS Soc (2014) 1.00
Correlation between lamivudine plasma concentrations and patient self-reported adherence to antiretroviral treatment in experienced HIV patients. Ther Clin Risk Manag (2011) 0.93
Virological failure and HIV-1 drug resistance mutations among naive and antiretroviral pre-treated patients entering the ESTHER program of Calmette Hospital in Cambodia. PLoS One (2014) 0.80
Relationship between viral load and behavioral measures of adherence to antiretroviral therapy in children living with human immunodeficiency virus in Latin America. Braz J Infect Dis (2015) 0.78
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet (2006) 10.91
Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis (2005) 9.23
Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS (2007) 5.97
Scaling up antiretroviral treatment in resource-poor settings. Lancet (2006) 5.51
Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis (2001) 5.43
Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS (2008) 5.26
Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS (2006) 5.13
Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis (2005) 4.96
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet (2004) 4.81
Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis (2004) 4.55
The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS (2002) 4.01
Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials (2004) 3.75
Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis (2003) 3.63
Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis (2007) 3.46
Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol (2005) 3.36
Access to antiretroviral drugs in Brazil. Lancet (2002) 2.21
Visual analog scale of ART adherence: association with 3-day self-report and adherence barriers. J Acquir Immune Defic Syndr (2006) 2.12
Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr (2006) 1.95
Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS (2007) 1.77
Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. J Acquir Immune Defic Syndr (2002) 1.70
Impact of a patient education program on adherence to HIV medication: a randomized clinical trial. J Acquir Immune Defic Syndr (2003) 1.69
Antiretroviral therapy adherence in Brazil. AIDS (2004) 1.57
Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antivir Ther (2003) 1.55
Adherence to antiretroviral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment. Antivir Ther (2008) 1.35
Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease. J Infect Dis (2003) 1.18
Macrocytosis as an indicator of medication (zidovudine) adherence in patients with HIV infection. AIDS Patient Care STDS (2002) 1.17
Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response. Clin Infect Dis (2001) 1.15
Forecast of demand for antiretroviral drugs in low and middle-income countries: 2007-2008. AIDS (2007) 1.09
Drug resistance and adherence to HIV/AIDS antiretroviral treatment: against a double standard between the north and the south. AIDS (2004) 0.94
The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination. AIDS (2003) 0.87
Antiretroviral treatment in resource-poor settings: what can we learn from the existing programmes in Thailand? AIDS (2004) 0.84
[Implementation of therapeutic education programmes for patients living with HIV in four low-income countries: an evaluative approach]. Sante Publique (2007) 0.77
[Implementation and assessment of an HIV treatment training program (2000-2001) for patients in Casablanca (Morocco)]. Sante (2005) 0.76
Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med (2011) 7.13
Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog (2013) 6.14
Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS (2005) 5.51
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet (2004) 4.81
Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission. Lancet (2013) 4.57
Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. Lancet (2013) 4.16
HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis (2005) 3.77
Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci U S A (2005) 3.37
Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA (2002) 2.91
Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr (2007) 2.72
SIVcpz in wild chimpanzees. Science (2002) 2.45
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest (2010) 2.43
Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr (2007) 2.32
African apes as reservoirs of Plasmodium falciparum and the origin and diversification of the Laverania subgenus. Proc Natl Acad Sci U S A (2010) 2.31
Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics (2007) 2.24
Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS (2008) 2.21
Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One (2008) 2.14
Foci of endemic simian immunodeficiency virus infection in wild-living eastern chimpanzees (Pan troglodytes schweinfurthii). J Virol (2003) 2.12
Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS (2004) 2.11
Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood (2009) 2.03
Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother (2010) 2.02
CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol (2004) 1.93
Risk factors for buruli ulcer: a case control study in Cameroon. PLoS Negl Trop Dis (2007) 1.90
Seasonal and regional dynamics of M. ulcerans transmission in environmental context: deciphering the role of water bugs as hosts and vectors. PLoS Negl Trop Dis (2010) 1.89
Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS (2007) 1.88
Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS Negl Trop Dis (2013) 1.86
Reduced CD4 T cell activation and in vitro susceptibility to HIV-1 infection in exposed uninfected Central Africans. Retrovirology (2006) 1.64
Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis (2005) 1.64
Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS (2006) 1.61
Weight gain at 3 months of antiretroviral therapy is strongly associated with survival: evidence from two developing countries. AIDS (2009) 1.60
Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses. J Virol (2007) 1.58
Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action. Clin Pharmacokinet (2010) 1.58
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet (2005) 1.58
Acquired hemophilia in older people: a poor prognosis despite intensive care. J Am Geriatr Soc (2007) 1.54
Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. J Infect Dis (2005) 1.54
The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS (2004) 1.52
Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis (2009) 1.50
Chimpanzee malaria parasites related to Plasmodium ovale in Africa. PLoS One (2009) 1.49
Demographic impact of AIDS in a low-fertility urban African setting: projection for Addis Ababa, Ethiopia. J Health Popul Nutr (2002) 1.46
Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med (2014) 1.45
Hospitalization criteria in imported falciparum malaria. J Travel Med (2007) 1.45
HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS (2006) 1.45
Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS (2004) 1.44
Absence of efficacy of nonviable Lactobacillus acidophilus for the prevention of traveler's diarrhea: a randomized, double-blind, controlled study. Clin Infect Dis (2006) 1.42
Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men. AIDS (2004) 1.42
Characteristics and long-term outcome of 15 episodes of systemic lupus erythematosus-associated hemophagocytic syndrome. Medicine (Baltimore) (2006) 1.41
Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaoundé, Cameroon. J Acquir Immune Defic Syndr (2003) 1.38
Risk factors for imported fatal Plasmodium falciparum malaria, France, 1996-2003. Emerg Infect Dis (2007) 1.37
Improved method for the simultaneous determination of d4T, 3TC and ddl intracellular phosphorylated anabolites in human peripheral-blood mononuclear cells using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom (2002) 1.31
Does transient HAART during primary HIV-1 infection lower the virological set-point? AIDS (2004) 1.31
Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali. J Antimicrob Chemother (2010) 1.29
Evolutionary relationships between bat coronaviruses and their hosts. Emerg Infect Dis (2007) 1.29
Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians. AIDS (2003) 1.29
Geographic expansion of Buruli ulcer disease, Cameroon. Emerg Infect Dis (2011) 1.28
Elevated IP10 levels are associated with immune activation and low CD4⁺ T-cell counts in HIV controller patients. AIDS (2014) 1.28
Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection. J Infect Dis (2003) 1.27
ISG15 is critical in the control of Chikungunya virus infection independent of UbE1L mediated conjugation. PLoS Pathog (2011) 1.26
Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Côte d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study. AIDS Res Hum Retroviruses (2009) 1.25
Early and long-lasting alteration of effector CD45RA(-)Foxp3(high) regulatory T-cell homeostasis during HIV infection. J Infect Dis (2012) 1.24
Molecular monitoring of causative viruses in child acute respiratory infection in endemo-epidemic situations in Shanghai. J Clin Virol (2010) 1.22
Resting regulatory CD4 T cells: a site of HIV persistence in patients on long-term effective antiretroviral therapy. PLoS One (2008) 1.21
High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. J Int AIDS Soc (2011) 1.21
Increase in at-risk sexual behaviour among HIV-1-infected patients followed in the French PRIMO cohort. AIDS (2002) 1.20
Liquid chromatography-tandem mass spectrometry assays for intracellular deoxyribonucleotide triphosphate competitors of nucleoside antiretrovirals. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.20
The hepatitis C virus epidemic in Cameroon: genetic evidence for rapid transmission between 1920 and 1960. Infect Genet Evol (2006) 1.19
Switch to second-line ART in West African routine care: incidence and reasons for switching. AIDS Care (2011) 1.19
Changing pattern of hepatitis C virus spread in rural areas of Egypt. J Hepatol (2005) 1.19
Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Antimicrob Agents Chemother (2010) 1.19
Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit Care (2008) 1.18
High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia. J Int AIDS Soc (2010) 1.18
Severe imported Plasmodium falciparum malaria, France, 1996-2003. Emerg Infect Dis (2011) 1.15
Cost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia. PLoS One (2010) 1.15
Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS One (2008) 1.14
Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Antimicrob Agents Chemother (2008) 1.14
Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1. AIDS (2009) 1.13
Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther (2004) 1.13
Analysis of IL28B variants in an Egyptian population defines the 20 kilobases minimal region involved in spontaneous clearance of hepatitis C virus. PLoS One (2012) 1.13
Prediction of treatment failure using 2010 World Health Organization Guidelines is associated with high misclassification rates and drug resistance among HIV-infected Cambodian children. Clin Infect Dis (2012) 1.12
Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS (2007) 1.11
Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS (2005) 1.11
Prolonged Plasmodium falciparum infection in immigrants, Paris. Emerg Infect Dis (2008) 1.10
Hepatitis C virus infection among pregnant women in Yaounde, Cameroon: prevalence, viremia, and genotypes. J Med Virol (2003) 1.09
Differential responses of the mosquito Aedes albopictus from the Indian Ocean region to two chikungunya isolates. BMC Ecol (2010) 1.09
Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol (2005) 1.09
Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis (2006) 1.08
Mycolactone impairs T cell homing by suppressing microRNA control of L-selectin expression. Proc Natl Acad Sci U S A (2011) 1.07
High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study. J Antimicrob Chemother (2009) 1.07
High rate of hepatitis C virus infection and predominance of genotype 4 among elderly inhabitants of a remote village of the rain forest of South Cameroon. J Med Virol (2003) 1.06